Document Detail


Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure.
MedLine Citation:
PMID:  16782216     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: In severe chronic heart failure (CHF) elevated serum levels of uric acid (UA) predict poor survival. This study investigates whether hyperuricaemia (defined as serum UA level > or = 6.5 mg/dL) extends its prognostic value on population with less advanced CHF. METHODS: We studied 119 consecutive patients with stable, mild-moderate CHF (88 men, age: 64+/-11 years, NYHA class I/II/III: 9/65/45, LVEF: 32+/-8%). RESULTS: Serum UA level (mean: 6.2+/-2.0 mg/dL, range: 2.0-16.2 mg/dL) increased in parallel to CHF severity expressed as NYHA class (4.9+/-1.1 vs. 5.7+/-1.5 vs. 7.2+/-2.4 mg/dL, NYHA I vs. II vs. III; NYHA I, II vs. III, p<0.01), inversely correlated with peak oxygen consumption (r=-0.39, p<0.01) and LVEF (r=-0.31, p<0.01), but not with renal function (expressed as creatinine clearance calculated from Cockcroft-Gault formula; r=-0.14, p>0.1), and predicted inflammatory status as evidenced by the correlation with C-reactive protein (r=0.31, p=0.003). Hyperuricaemia was detected in 48 (40%) patients. During follow-up (mean: 580+/-209 days, > 18 months in all survivors), 27 (23%) patients died. Hyperuricaemia was related to impaired survival in univariate (HR 2.8, 95%CI: 1.3-6.1, p=0.01) and multivariate analyses (adjusted for NYHA class and impaired renal function--the only mortality predictors in this population; p<0.05). The 18-month survival for CHF patients with hyperuricaemia was 71% (95% CI: 58-84%) vs. 89% (95% CI: 81-96%) in those with normal UA level (p=0.01). CONCLUSION: In patients with mild-moderate CHF, hyperuricaemia predicts exercise intolerance and inflammatory activation and is strongly and independently related to poor prognosis. Whether elevated serum UA level may become a novel therapeutic target in CHF, deserves further studies.
Authors:
Ewa A Jankowska; Beata Ponikowska; Jacek Majda; Robert Zymlinski; Mieczyslaw Trzaska; Krzysztof Reczuch; Ludmila Borodulin-Nadzieja; Waldemar Banasiak; Piotr Ponikowski
Related Documents :
18403456 - Physical exercise improves plasmatic levels of il-10, left ventricular end-diastolic pr...
15012916 - Basal and exercise-induced neuroendocrine activation in patients with heart failure and...
17478726 - Effect of k+atp channel and adenosine receptor blockade during rest and exercise in con...
16160606 - Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than...
8149936 - Metabolic cost and efficiency in two forms of squatting exercise in children and adults.
22276986 - Cardiac autonomic function and cardiovascular response to exercise in patients with chr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-06-19
Journal Detail:
Title:  International journal of cardiology     Volume:  115     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-01-29     Completed Date:  2007-04-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  151-5     Citation Subset:  IM    
Affiliation:
Cardiology Department, Military Hospital, ul. Weigla 5, 50-981 Wroclaw, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chronic Disease
Female
Heart Failure / blood,  complications*
Humans
Hyperuricemia / complications*
Male
Middle Aged
Prognosis
Severity of Illness Index
Uric Acid / blood
Chemical
Reg. No./Substance:
69-93-2/Uric Acid
Comments/Corrections
Comment In:
Int J Cardiol. 2007 Feb 7;115(2):156-8   [PMID:  16844250 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dr...
Next Document:  The future of gene therapy in the UK.